Sekisui Medical Co.

Tokyo, Japan

Sekisui Medical Co.

Tokyo, Japan
SEARCH FILTERS
Time filter
Source Type

Patent
National Cancer Center and Sekisui Medical Co. | Date: 2017-01-04

It is intended to provide a rapid, convenient, and highly accurate method for determining the prognosis of cancer. The present invention provides a method for determining the prognosis of a renal cell carcinoma patient, comprising: (1) treating genomic DNA prepared from a renal tissue of a subject with bisulfite; (2) amplifying the bisulfite-treated DNA by PCR; (3) subjecting the obtained PCR amplification product to ion exchange chromatography; (4) obtaining the retention time of a detection signal obtained by the chromatography; and (5) determining the renal cell carcinoma of the subject as having poor prognosis when the result of the step (4) is shorter than a retention time serving as a reference.


Patent
Sekisui Medical Co. | Date: 2017-02-08

A problem to be solved by the present invention is to provide an acylcarnitine composition easy to handle in a solution state and having long-term storage stability. The problem is solved by an acylcarnitine composition characterized by having at least one or more acylcarnitines dissolved in an organic solvent containing an organic acid.


Patent
National Cancer Center and Sekisui Medical Co. | Date: 2015-03-02

It is intended to provide a rapid, convenient, and highly accurate method for determining the prognosis of cancer. The present invention provides a method for determining the prognosis of a renal cell carcinoma patient, comprising: (1) treating genomic DNA prepared from a renal tissue of a subject with bisulfite; (2) amplifying the bisulfite-treated DNA by PCR; (3) subjecting the obtained PCR amplification product to ion exchange chromatography; (4) obtaining the retention time of a detection signal obtained by the chromatography; and (5) determining the renal cell carcinoma of the subject as having poor prognosis when the result of the step (4) is shorter than a retention time serving as a reference.


A problem to be solved by the present invention is to provide an immunochromatographic test strip and a detection method using immunochromatography avoiding aggregation of colloidal gold conjugates while red blood cells in whole blood are agglutinated and then separated and removed in the case of using polybrene as a blood-agglutinating agent and the colloidal gold conjugates as a detection reagent. To solve the problem, the present inventers reviewed a past reagent configuration itself from a completely different viewpoint rather than selecting type and amount of polyanions and, as a result of extensive study on each element, the inventers surprisingly found that aggregation of colloidal gold can be suppressed by using a certain buffer solution without using neutralization by polyanions.


A problem to be solved by the present invention is to provide an immunochromatographic test strip and a detection method using immunochromatography avoiding aggregation of colloidal gold conjugates while red blood cells in whole blood are agglutinated and then separated and removed in the case of using polybrene as a blood-agglutinating agent and the colloidal gold conjugates as a detection reagent. To solve the problem, the present inventers reviewed a past reagent configuration itself from a completely different viewpoint rather than selecting type and amount of polyanions and, as a result of extensive study on each element, the inventers surprisingly found that aggregation of colloidal gold can be suppressed by using a certain buffer solution without using neutralization by polyanions.


Patent
Sekisui Medical Co. | Date: 2015-03-31

A problem to be solved by the present invention is to provide an acylcarnitine composition easy to handle in a solution state and having long-term storage stability. The problem is solved by an acylcarnitine composition characterized by having at least one or more acylcarnitines dissolved in an organic solvent containing an organic acid.


Patent
Sekisui Medical Co. | Date: 2017-09-20

Provided is a blood separating agent that can form an excellent partition wall in an intermediate layer between clot and serum or between blood cell components and plasma even under low-temperature centrifugation conditions, is less likely to form crevices in the partition wall, is less likely to have any effect on test values, and offers stable performance even after long-term storage. The blood separating agent contains: a polymer for the blood separating agent which is composed of a (meth)acrylic acid ester-based polymer and has a viscosity of 10 to 200 Pas at 25C; an inorganic powder; and a polyalkylene glycol having a number average molecular weight of 700 or more, wherein the polyalkylene glycol is mixed at a concentration of 5% by weight or less of the total weight of the blood separating agent.


Patent
Sekisui Medical Co. | Date: 2017-09-27

Provided is a container for preparing a diluted solution of a biological sample to be used for biological sample analysis. Specifically, provided is a container for specimen dilution, including: an open; a first bottom; a second bottom formed on an inner side wall of the container; and a groove upwardly formed, on the inner side wall of the container, from the second bottom, in which the groove has a constant width equal to a width of the second bottom, or the groove has, at a lower end thereof, a width equal to the width of the second bottom and upwardly widens.


Patent
Sekisui Medical Co. | Date: 2016-01-20

A cylindrical column body (101) holds a filler. A pair of end caps (105, 106) covers both ends of the column body (101) and has a flow hole for a carrier liquid (111, 112) arranged in the center thereof. An end surface on the side of a large diameter portion (113a, 114a) of a pair of columnar joint members (113, 114) contacts an end surface of the pair of end caps (105, 106) and also has a communication hole (115, 116) arranged in the center thereof. A sealing member (117, 118) is arranged on a contact surface between the end cap (105, 106) and the joint member (113, 114). A bottomed cylindrical case (121) accommodates the pair of end caps (105, 106) and a large diameter portion of the pair of joint members (113, 114) in an engaged state. A cover member (124) is detachably installed on a side of an opening of the case (121).


Patent
Sekisui Medical Co. | Date: 2016-04-13

The present invention provides a particle enhanced agglutination immunoassay including the steps of: mixing a sample solution containing an analyte with a solution containing insoluble carrier particles carrying a binding partner or binding partners for the analyte to prepare a mixed solution; determining a variation (i) in intensity of light scattered from the mixed solution based on a difference in intensity of scattered light between first and second time points; determining a variation (ii) in absorbance of the mixed solution based on a difference in absorbance between third and fourth time points; and correlating the determined variation (i) in intensity of scattered light and the determined variation (ii) in absorbance with an amount of the analyte present in the sample using a calibration curve plotted based on the variation in intensity of scattered light and a calibration curve plotted based on the variation in absorbance. The present invention employs measurements of the intensity of scattered light and the absorbance in combination for a single assay, and thus provides a particle enhanced agglutination immunoassay which achieves higher sensitivity and a wider dynamic range than conventional assays.

Loading Sekisui Medical Co. collaborators
Loading Sekisui Medical Co. collaborators